Arcutis Biotherapeutics ARQT 深 沪
等待开盘 05-16 09:30:00 美东时间
21.32
-0.250
-1.16%
华盛通- 最 高21.835
- 今 开21.13
- 成交量 160.05万股
- 最 低 21.005
- 昨 收 21.57
- 总市值 26.67亿
- 52周最高 31.77
- 市盈率 静 --
- 换手率 1.28%
- 52周最低 12.72
- 委 比 88.38%
- 总股本 1.25亿
- 历史最高 40.88
- 量 比 0.58
- 振 幅 3.85%
- 历史最低 1.76
- 每 手 1
- 风险率 5.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arcutis Earnings Call Signals Momentum Amid Headwinds
Arcutis Biotherapeutics Inc (($ARQT)) has held its Q1 earnings call. Read on fo...
05-11 08:23
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics granted 40 new employees 269,000 restricted stock units and options for 70,000 shares under its 2022 Inducement Plan. The awards, approved by the Compensation Committee, vest over four years, with 25% vesting annually for restricted stock units and 25% on the first anniversary for options, followed by monthly vesting over three years. The stock options have a 10-year term and an exercise price of $23.35 per share, based on...
05-08 20:00
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $36 Price Target
Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $36 price target.
05-07 18:48
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
财报速睇 | Arcutis Biotherapeutics 2026财年Q1营收1.05亿美元，同比增长60.1%；归母净利润亏损0.11亿美元，同比亏损缩窄54.9%
华盛资讯5月7日讯，Arcutis Biotherapeutics公布2026财年Q1业绩，公司Q1营收1.05亿美元，同比增长60.1%，归母净利润亏损0.11亿美元，同比亏损缩窄54.9%。
05-07 04:36
Arcutis director Howard Welgus sells 7,144 shares for $164,203.54
Arcutis director Howard Welgus sells 7,144 shares for $164,203.54 Arcutis Biotherapeutics director Howard G. Welgus sold 7,144 common shares on May 1, 2026. Sale priced at weighted average USD 22.99 per share. Direct holdings stood at 32,600 shares following transaction. Disclaimer: This news brief
05-06 08:22
Arcutis Biotherapeutics Announces Submission Of sNDA To FDA Seeking To Expand Indication For ZORYVE Cream 0.05% To Include Topical Treatment Of Atopic Dermatitis In Infants Down To 3 Months
Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitisOnce-daily ZORYVE cream was well tolerated with a safety
04-27 20:04
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
Arcutis Biotherapeutics submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval to expand the use of ZORYVE cream 0.05% to treat mild to moderate atopic dermatitis in infants as young as 3 months. The submission is supported by positive results from the Phase 2 INTEGUMENT-INFANT trial, which showed the cream was well-tolerated and effective in reducing symptoms in infants aged 3 months to less than 24 months. Currently, o...
04-27 12:00
Top 10 Healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x
A Bank of America Global Research chart tracking healthcare R&D-to-sales ratios and relative forward PE versus the S&P 500 from 1990 to March 2026 shows both metrics declining in tandem over decades, ...
04-17 04:04
